Articles

Illumina expands genomics accelerator to Cambridge

Company partners with leading European venture capital firms to build genomics startups
Brought to you byDDNews Staff
| 2 min read

SAN DIEGO—This summer, llumina Inc. announced the global expansion of Illumina Accelerator to Cambridge in the United Kingdom. Founded in the San Francisco Bay Area in 2014, Illumina Accelerator is a company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups.

Illumina Accelerator notes that this is its first international location and will represent its Europe, Middle East and Africa (EMEA) headquarters for the startup venture. The inaugural funding cycle of Illumina Accelerator Cambridge will begin in Spring 2020.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
Blue microscopic illustration of spherical cells with textured surfaces against a dark background.
Explore how longitudinal single-cell profiling of whole blood can reveal immune signatures associated with CAR T cell therapy-related neurotoxicity.